PRESS RELEASE Astellas Pharma Inc.

We are delighted that our partner Astellas can be applying its assets and pharmaceutical development knowledge to Anokion’s platform technology and immunology knowledge, through our new organization Kanyos, said Jeffrey A. Hubbell, Professor of Molecular Engineering at the University of Chicago, Professor of Bioengineering at the Ecole Polytechnique Fédérale de Lausanne, and the academic founder, Chairman and Chief Scientific Officer of both Anokion and Kanyos. Our combined team has an possibility to make a profound impact on patients’ lives. I am very happy to enter into this agreement with Anokion, under which we will be developing exclusive and innovative items for antigen-specific immune tolerance, said Kenji Yasukawa, Ph.D., Senior Vice Chief and President Strategy Officer of Astellas.Ahead of being accepted in to the study, participants would undergo a true number of lab tests including blood work and a physical. If accepted for participation in the trial, individuals will need a hydroxychloroquine pill each day for two weeks leading up to surgery. Participants will keep a pill diary and undergo periodic bloodstream work during this right time. For more info on how to take part, individuals should contact CINJ’s Office of Individual Research Services at 732-235-8675 or e-mail .

American University of Gastroenterology develops fresh podcast for Globe Digestive Health Day For World Digestive Health Day, the American University of Gastroenterology, along with World Gastroenterology Organisation , observes the 2014 concentrate on the individual gut microbiome and its own impact on health and disease.